STATEMENT OF NEED

Non–small lung cancer (NSCLC) is a biologically diverse type of lung cancer driven by a wide array of molecular alterations. Human epidermal growth factor receptor 2 (HER2) alterations occur in approximately 4% of patients with NSCLC and include gene mutations, gene amplifications, and protein overexpression. HER2-targeted therapies, including antibody-drug conjugates and tyrosine kinase inhibitors, have shown promising efficacy for patients with limited treatment options. Testing for HER2 alterations is crucial in order to identify patients who may benefit from targeted therapies, and interprofessional collaboration is critical to optimizing timely diagnosis and personalized management throughout the care continuum (Ismail et al, 2025). In this live webinar, Maria Arcila, MD, Anatomic and Clinical Pathologist and Director of the Diagnostic Molecular Pathology Laboratory at Memorial Sloan Kettering Cancer Center, and Helena A. Yu, MD, Attending Physician and Thoracic Medical Oncologist at Memorial Sloan Kettering Cancer Center, will explore strategies for closing the gap between detection and optimal treatment in NSCLC with HER2 alterations. 

TARGET AUDIENCE

Oncologists, molecular pathologists, radiologists, thoracic surgeons, pulmonologists, advance practice providers, and other healthcare professionals (HCPs) working across community health systems, academic medical centers, and integrated delivery involved in the management of patients with non–small cell lung cancer (NSCLC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Describe the epidemiology, clinical implications, and diagnostic challenges of HER2-mutant NSCLC
• Interpret NGS reports to identify HER2 mutations and integrate this data into treatment planning
• Evaluate current and emerging treatment options for HER2-mutant NSCLC 
• Apply interprofessional strategies to enhance timely diagnosis, testing, and communication across the care continuum for patients with HER2-mutant NSCLC

 
REGISTRATION

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 1/26/26. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Maria E. Arcila, MD, discloses that she has served on an advisory board or panel for Biocartis and that she has served as a consultant for AstraZeneca and Biocartis.

Helena A. Yu, MD, discloses that she has served on an advisory board or panel for AbbVie, Amgen, AstraZeneca, Cullinan, Daiichi Sankyo, Janssen, SystImmune, Taiho, and Takeda; and that she has received grants/research support from AstraZeneca, BeOne, Cullinan, Daiichi Sankyo, Janssen, Kumquat, Pfizer, SystImmune, and Taiho. 

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.

TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD | CPE ACTIVITIES

For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CPE activities, include access to system requirements:

• The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
• The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Aggregate participant data will be shared with commercial supporters of this activity.

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.